Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.53 |
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591038 | 0.88 | ACE (0.57) | F2OPRM1OPRD1ACEBDKRB2 | |
| SCHEMBL31510132 | 0.86 | F2 (0.60) | F2OPRM1OPRD1ACEOPRK1 | |
| SCHEMBL31031584 | 0.85 | OPRM1 (0.60) | F2OPRM1OPRD1BDKRB2OPRK1 | |
| SCHEMBL31756935 | 0.84 | F2 (0.65) | F2OPRM1OPRD1ACEOPRK1 | |
| SCHEMBL31513749 | 0.83 | OPRM1 (0.59) | F2OPRM1OPRD1ACE | |
| SCHEMBL31505799 | 0.82 | F2 (0.58) | F2OPRM1OPRD1ACEOPRK1 | |
| SCHEMBL30798900 | 0.81 | ACE (0.55) | F2OPRM1OPRD1ACEBDKRB2 | |
| SCHEMBL31362717 | 0.81 | OPRM1 (0.55) | F2OPRM1OPRD1ACEOPRK1 | |
| SCHEMBL30658583 | 0.81 | F2 (0.58) | F2OPRM1OPRD1ACEOPRK1 | |
| SCHEMBL29590494 | 0.81 | OPRM1 (0.51) | F2OPRM1OPRD1ACEBDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11719705-B2 | IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making | INDI MOLECULAR, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11719705-B2 | IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making | IL17A, IL23R, IL15 | F2 2088/4885OPRM1 4780/4885OPRD1 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.